Knight Therapeutics (GUD) Q4 2024 earnings summary

Executive summary

• Achieved record revenues in 2024, reaching over CAD 365 million (adjusted $365.4M), up 6% year-over-year, with promoted products accounting for 75% of total revenues and a three-year CAGR exceeding 30%.

• Net income reached $4.3M versus a net loss of $16.8M in 2023; EPS improved to $0.04 from a loss of $0.16.

• Expanded pipeline with five new products and regulatory submissions for Qelbree and Tavalis; four innovative and five branded generic products pending approval.

• Launched Minjuvi in Brazil, Bijuva and Imvexxy in Canada, and obtained regulatory approvals for Minjuvi, Tavalis, Jornay PM, and Pemazir in various territories.

• Announced acquisition of Paladin assets for CAD 100 million ($120M) plus inventory, expected to close mid-2025, adding CAD 70 million in revenues and stable cash flow products.

Financial highlights

• 2024 revenues reached over CAD 365 million (adjusted $365.4M), up 6% year-over-year; Q4 revenues were over CAD 94 million ($96.9M), up 6% (31% in USD), with $17.0M attributed to hyperinflation in Argentina.

• Oncology and hematology portfolio delivered CAD 137.6 million, up 12% year-over-year; infectious diseases portfolio delivered $149 million, up 6%.

• Gross margin for 2024 was CAD 173 million ($174.4M), 47% of revenues, slightly down from 48% last year due to product mix.

• Adjusted EBITDA for 2024 was CAD 57.8 million ($57.8M), down 4% year-over-year; adjusted EBITDA per share was CAD 0.58 ($0.58), flat to down 2%.

• Cash inflow from operations totaled $36.3M, with financial assets valued at CAD 134 million ($142.3M) at year-end.

Outlook and guidance

• 2025 revenue guidance: CAD 390–405 million ($390M–$405M); adjusted EBITDA expected at ~13% of revenues, reflecting investments in new launches and pipeline advancement.

• EBITDA margin decrease due to launch investments for Jornay PM and Minjuvi, and pipeline development.

• Paladin acquisition expected to close mid-2025, adding scale and stable cash flows to Canadian operations.

• Guidance assumes no material hyperinflation adjustment in Argentina, successful Paladin closing, and no major disruptions or new generic entrants.

• More than half of the CAD 150 million peak sales potential from pipeline expected from near-term launches.